Clinical Research Papers:
The expression of plakoglobin is a potential prognostic biomarker for patients with surgically resected lung adenocarcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1234 views | HTML 1535 views | ?
Xiaobo He1,2,3,*, Ting Zhou1,2,3,*, Guangwei Yang1,4,*, Wenfeng Fang1,2,3, Zelei Li1,2,3, Jianhua Zhan1,2,3, Yuanyuan Zhao1,2,3, Zhibin Cheng4, Yan Huang1,2,3, Hongyun Zhao1,2,3 and Li Zhang1,2,3
1 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China
2 State Key Laboratory of Oncology in South China, Guangzhou, China
3 Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
4 Department of Oncological Radiotherapy, the Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, China
* These authors have contributed equally to this work and share the first authorship
Li Zhang, email:
Keywords: adenocarcinoma; biomarker; immunohistochemistry; plakoglobin; prognosis in surgically resected lung adenocarcinoma
Received: August 24, 2015 Accepted: February 05, 2016 Published: February 25, 2016
Purpose: This study aimed to explore the relationship between plakoglobin expression and clinical data in the patients with surgically resected lung adenocarcinoma.
Results: With follow-up of median 50.14 months, the average PFS and OS were 16.82 and 57.92 months, respectively. In 147 patients, recurrence or death was observed in 131 patients. According to the log-rank test, low plakoglobin expression was a significant predictor for favorable DFS (P=0.006) and OS (P=0.043). For the analyses within subgroups, high plakoglobin expression was an independent factor for reducing DFS in non-metastatic patients with resected lung adenocarcinoma (P < 0.05). Moreover, high plakoglobin expression was associated with poor DFS even receiving adjuvant chemotherapy (P =0.028) and with a shorter DFS (HR, 2.01, 95%CIs, 1.35 to 2.97, P=0.001) and OS (HR, 1.94, 95%CIs, 1.12 to 3.37, P=0.019).
Patients and methods: The expression of plakoglobin in 147 primary tumor tissues was examined by using immunohistochemistry and clinical data were collected. The optimal cutoff value of immunoreactivity score (IRS) was calculated and used to divide all the patients into two groups: low-level group (IRS: 0-3, n=59) and high-level group (IRS: 4-12, n=88). Kaplan–Meier curves were applied to assess the plakoglobin expression and clinical variables. The univariate and multivariate Cox model analyses were performed to evaluate the effects of clinical factors and plakoglobin expression on disease-free survival (DFS) and overall survival (OS).
Conclusion: High plakoglobin expression is an independent negative prognostic factor for patients with surgically resected lung adenocarcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.